EcoDrugPlus

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSMZEG00005023436
Gene Symbol: LOC101479745
3 Cross references
197 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret

Ensembl ID : ENSMZEG00005011427
Gene Symbol: LOC101475370
3 Cross references
203 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret-Like

Ensembl ID : ENSMZEG00005025032
Gene Symbol: LOC112434355
3 Cross references
201 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSMZEG00005020072
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSMZEG00005001213
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSMZEG00005014232
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Putative N-Acetylated-Alpha-Linked Acidic Dipeptidase

Ensembl ID : ENSMZEG00005024532
Gene Symbol: LOC101476953
3 Cross references
335 Possible Orthologues:

Putative N-Acetylated-Alpha-Linked Acidic Dipeptidase

Ensembl ID : ENSMZEG00005023669
Gene Symbol: LOC112429880
3 Cross references
337 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSMZEG00005005996
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSMZEG00005014171
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSMZEG00005014637
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity-Modifying Protein 1

Ensembl ID : ENSMZEG00005000875
Gene Symbol: LOC101467429
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).